The therapeutic targeting of MALT1 protease activity is a potential approach for the treatment of lymphomas or an effective strategy for treating neoplastic and inflammatory disorders associated with dysregulated NF-κB signaling [24,25]. This evidence concerns the gene NFKB1 and lymphoma.